Actigenomics

ACT Genomics is a leading precision oncology company based in Asia that specializes in comprehensive genomic profiling and molecular diagnostics to guide cancer treatment. The company utilizes next-generation sequencing (NGS) technology and proprietary bioinformatics to analyze tumor tissue and liquid biopsies, identifying actionable mutations for targeted therapy and immunotherapy selection. Their flagship products, including ACTOnco and ACTLiquid, provide clinicians and pharmaceutical partners with critical data for personalized patient care and biomarker discovery. Following its acquisition by Prenetics in 2023, ACT Genomics has continued to expand its clinical services and research collaborations across the Asia-Pacific region.